
CorMedix (CRMD) Stock Forecast & Price Target
CorMedix (CRMD) Analyst Ratings
Bulls say
Cormedix Inc. is poised for significant growth, particularly with its product DefenCath, which is projected to see improved pricing and increased sales following enhanced reimbursement from CMS and its expansion into total parenteral nutrition (TPN). Management’s long-term financial guidance indicates expected DefenCath sales of $100 million to $140 million by 2027, reflecting confidence in the product's market potential and the predictive nature of the TDAPA formula that anticipates a 3x-5x improvement in pricing. Additionally, the successful integration of the Momenta acquisition, which contributed approximately $140 million in pro forma revenue and generated operational synergies exceeding $35 million within mere months, further solidifies Cormedix's operational foundation and indicates a strong trajectory for future growth.
Bears say
Cormedix Inc. has issued revenue guidance for 2026 and 2027 that falls significantly short of analyst expectations, leading to a negative outlook for the company. The guidance indicates a top-line revenue of $300 million to $320 million, which is a decrease from the previous projections of approximately $400 million for 2025, primarily driven by anticipated declines in DefenCath sales due to competitive pressures and revenue cliffs after mid-2026. Additionally, there are concerns regarding the potential for high discontinuation rates associated with DefenCath and competition from generics, which may further impact sales and market penetration.
This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.
CorMedix (CRMD) Analyst Forecast & Price Prediction
Start investing in CorMedix (CRMD)
Order type
Buy in
Order amount
Est. shares
0 shares